EMAIL THIS PAGE TO A FRIEND

British journal of pharmacology

Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism.


PMID 25065395

Abstract

The most common mutation in cystic fibrosis (CF), F508del, causes defects in trafficking, channel gating and endocytosis of the CF transmembrane conductance regulator (CFTR) protein. Because CF is an orphan disease, therapeutic strategies aimed at improving mutant CFTR functions are needed to target the root cause of CF. Human CF airway epithelial cells were treated with roscovitine 100 μM for 2 h before CFTR maturation, expression and activity were examined. The mechanism of action of roscovitine was explored by recording the effect of depleting endoplasmic reticulum (ER) Ca(2+) on the F508del-CFTR/calnexin interaction and by measuring proteasome activity. Of the cyclin-dependent kinase (CDK) inhibitors investigated, roscovitine was found to restore the cell surface expression and defective channel function of F508del-CFTR in human CF airway epithelial cells. Neither olomoucine nor (S)-CR8, two very efficient CDK inhibitors, corrected F508del-CFTR trafficking demonstrating that the correcting effect of roscovitine was independent of CDK inhibition. Competition studies with inhibitors of the ER quality control (ERQC) indicated that roscovitine acts on the calnexin pathway and on the degradation machinery. Roscovitine was shown (i) to partially inhibit the interaction between F508del-CFTR and calnexin by depleting ER Ca(2+) and (ii) to directly inhibit the proteasome activity in a Ca(2+) -independent manner. Roscovitine is able to correct the defective function of F508del-CFTR by preventing the ability of the ERQC to interact with and degrade F508del-CFTR via two synergistic but CDK-independent mechanisms. Roscovitine has potential as a pharmacological therapy for CF.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

C4731
Anti-Calnexin antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
HPA009433
Anti-CANX antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA009696
Anti-CANX antibody produced in rabbit, Ab2, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB5200084
Anti-CANX antibody produced in rabbit, whole antiserum
SAB5200097 Anti-CANX antibody produced in rabbit, affinity isolated antibody
SAB1405577
Anti-CD8A antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA037756
Anti-CD8A antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
C7491 Anti-CFTR antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA021939
Anti-CFTR antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4501942
Anti-CFTR antibody produced in rabbit, affinity isolated antibody
CKOZFN1722 CompoZr® Knockout ZFN Kit, Human CFTR (NM_000492)
CKOZFND1161 CompoZr® Knockout ZFN Kit, ZFN plasmid only, Human CFTR (NM_000492)
CKOZFND1722 CompoZr® Knockout ZFN Kit, ZFN plasmid only, Human CFTR (NM_000492)
EHU020491 MISSION® esiRNA, esiRNA human CFTR (esiRNA1)
C7423
Monoclonal Anti-CD8 antibody produced in mouse, clone UCHT-4, purified immunoglobulin, buffered aqueous solution
SAB4700084 Monoclonal Anti-CD8 antibody produced in mouse, clone MEM-31, purified immunoglobulin, buffered aqueous solution
SAB4700089 Monoclonal Anti-CD8 antibody produced in mouse, clone MEM-87, purified immunoglobulin, buffered aqueous solution
SAB1402142
Monoclonal Anti-CD8A antibody produced in mouse, clone 4B9, purified immunoglobulin, buffered aqueous solution